Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients

Journal of Infection

Volumn 55, Issue 6, 2007, Pages 484-487

  Salvana, Edsel Maurice T ^a   Cooper, Gregory S ^a   Salata, Robert A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infliximab; IRIS; MAC; MOTT

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CIPROFLOXACIN; ETHAMBUTOL; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; RIFAMPICIN; STEROID; VANCOMYCIN;

ADULT; ANAMNESIS; ANTIBIOTIC SENSITIVITY; BLOOD CULTURE; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; GENE PROBE; HUMAN; LUNG LAVAGE; MALNUTRITION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PARENTERAL NUTRITION; REVIEW; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, ATYPICAL;

EID: 36049039854     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.08.007     Document Type: Review

References (20)

1. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous disease and TNF antagonists. Clin Infect Dis 38 (2004) 1261-1265
2. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44 (2005) 714-720
3. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al., The RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8 (2006) R114 [Epub ahead of print]
4. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 (2006) 717-722
5. Marie I., Heliot P., Roussel F., Herve F., Muir J.F., and Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 44 (2005) 1201-1202
6. Mufti A.H., Toye B.W., Mckendry R.R., and Angel J.B. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 53 (2005) 233-238
7. Okubo H., Iwamoto M., Yoshio T., Okazaki H., Kato T., Bandoh M., et al. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheumatol 15 (2005) 62-64
8. Boulman N., Rozenbaum M., Slobodin G., and Rosner I. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 723
9. Shelburne III S.A., and Hamill R.J. The immune reconstitution inflammatory syndrome. AIDS Rev 5 (2003) 67-79
10. Garcia-Vidal C., Rodriguez Fernandez S., Martinez Lacasa J., Salavert M., Vidal R., Rodriguez Carballeira M., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40 (2005) 756-759
11. Belknap R., Reves R., and Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 9 (2005) 1057-1058
12. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
13. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
14. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
15. American College of Rheumatology Hotline. FDA advisory committee reviews safety of TNF inhibitors, Available from: [accessed on 28.12.06].
16. Mow W.S., Abreu-Martin M.T., Papadakis K.A., Pitchon H.E., Targan S.R., and Vasiliauskas E.A. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2 (2004) 309-313
17. Peno-Green L., Lluberas G., Kingsley T., and Brantley S. Lung injury linked to etanercept therapy. Chest 122 (2002) 1858-1860
18. Phillips K., Husni M.E., Karlson E.W., and Coblyn J.S. Experience with etanercept in an academic medical center: are infection rates increased?. Arthritis Rheum 47 (2002) 17-21
19. Jaffery S.H., Carrillo M., and Betensley A.D. Fatal pulmonary nontuberculous mycobacterial infection in a patient receiving etanercept for rheumatoid arthritis. Chest 126 (2004) 944S-945S
20. Fennelly K., and Iseman M.D. Etanercept or Mycobacterium lung injury?. Chest 124 (2003) 1174